Unlock the Future of Type 2 Diabetes Care

Hosted by Nancy Hanna

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

Dive into the groundbreaking SECURE T2D study, the largest and most diverse trial ever conducted on Automated Insulin Delivery (AID) for people with type 2 diabetes. Discover how Omnipod 5 demonstrated improvements in A1C levels, increased time in range (TIR), and participant-reported reduction in Diabetes Distress. Dr. Viral Shah from the Indiana University School of Medicine, and an investigator in this trial, reveals key insights on how Omnipod 5 can help simplify diabetes management.

Don’t miss this chance to learn how Omnipod 5 can enhance your care for your patients living with type 2 diabetes.

Time stamps

2:54 – SECURE T2D: the most racially diverse study of AID in type 2 diabetes - a highly representative cohort of the population with type 2 diabetes
4:49 – Key results from the Secure T2D study
6:08 – Omnipod 5 changing the type 2 diabetes treatment paradigm
 

 

This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.

Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.